




UNIVERSITY OF BARI  
"ALDO MORO"

DEPARTMENT OF INTERNAL MEDICINE AND CLINICAL ONCOLOGY

# INNOVATION IN CLINICAL ONCOLOGY: oncogenomics for diagnosis and treatment



Presidents: **Franco Dammacco, Franco Silvestris**

Bari, June 23<sup>rd</sup>-24<sup>th</sup>, 2016

Villa Romanazzi Carducci

Scientific Program

# UNDER THE AUSPICES OF:



COMUNE DI BARI



# Presentation

Following the human genome project, extensive oncogenomic studies have been carried out in the last two decades worldwide. The results of these ongoing efforts have allowed to achieve major advancements in cancer diagnosis and treatment, including the definition of the gene derangements that initiate and drive the development of tumors, new molecular classifications useful for novel diagnoses, prediction of clinical outcome, identification of structural gene targets, and insights and strategies for individualizing cancer treatment. In addition, targeted therapies by small molecules, acting as intracellular signaling blockers or immune checkpoint inhibitors in novel immunotherapy protocols, have resulted in substantial increase of clinical response rates and a remarkable improvement of overall survival in a number of solid cancers.

The aim of this meeting is to revisit and provide an in-depth analysis of the most recent advances in basic and clinical application of molecular medicine to the diagnosis and treatment of major tumors, whose genomic profiles are now considered essential drivers for therapeutic decisions and clinical research.

We would like to deeply thank and heartily welcome the foreign and Italian basic scientists and dedicated clinical investigators, who have kindly accepted our invitation to deliver state-of-the-art lectures, exciting updates and relevant results of their own studies on cutting edge topics in the field of molecular medicine related to clinical oncology. We are also trustful that the participants in this meeting, and especially the youngest among them, will share our enthusiasm for the modern approach to clinical oncology by the fashionable tool of molecular medicine.

Franco Dammacco

Franco Silvestris

# Chairmen and Speakers

M. Aglietta  
*(Candiolo, I)*

G. Aprile  
*(Udine, I)*

G. Arpino  
*(Naples, I)*

P.A. Ascierio  
*(Naples, I)*

S. Bambace  
*(Barletta, I)*

M. Battaglia  
*(Bari, I)*

S. Bracarda  
*(Arezzo, I)*

M. Brandi  
*(Barletta, I)*

P. Cafforio  
*(Bari, I)*

S. Cascinu  
*(Ancona, I)*

S. Cinieri  
*(Brindisi, I)*

P. Conte  
*(Padua, I)*

L. Crinò  
*(Perugia, I)*

F. Dammacco  
*(Bari, I)*

J. De Bono  
*(London, UK)*

F. De Braud  
*(Milan, I)*

R. De Maria  
*(Rome, I)*

S. De Placido  
*(Naples, I)*

M. Del Vecchio  
*(Milan, I)*

A. Falcone  
*(Pisa, I)*

G. Giudice  
*(Bari, I)*

M. Giuliano  
*(Naples, I)*

G. Gorgoni  
*(Bari, I)*

R. Labianca  
*(Bergamo, I)*

L. Landi  
*(Livorno, I)*

J. Ledermann  
*(London, UK)*

G. Lo Russo  
*(Milan, I)*

V. Lorusso  
*(Bari, I)*

G. Loverro  
*(Bari, I)*

E. Maiello  
*(San G. Rotondo, I)*

M. Maio  
*(Siena, I)*

E. Maiorano  
*(Bari, I)*

P. Marchetti  
*(Rome, I)*

F. Marincola  
*(Doha, Qatar)*

T. Meyer  
*(London, UK)*

L. Miele  
*(New Orleans, US)*

M. Montagnani  
*(Bari, I)*

F. Montemurro  
*(Candiolo, I)*

E. Munzone  
*(Milan, I)*

N. Normanno  
*(Naples, I)*

G. Palmieri  
*(Sassari, I)*

R. Palmirota  
*(Bari, I)*

M.A. Pantaleo  
*(Bologna, I)*

P. Pinzani  
*(Florence, I)*

C. Porta  
*(Pavia, I)*

P. Queirolo  
*(Genoa, I)*

F. Raspagliesi  
*(Milan, I)*

L. Resta  
*(Bari, I)*

N. Resta  
*(Bari, I)*

M. Rocchi  
*(Bari, I)*

G. Rubini  
*(Bari, I)*

A. Russo  
*(Palermo, I)*

G.V. Scagliotti  
*(Turin, I)*

A. Scarpa  
*(Verona, I)*

F. Silvestris  
*(Bari, I)*


G. Surico  
*(Lecce, I)*

P. Tagliaferri  
*(Catanzaro, I)*

M. Tucci  
*(Bari, I)*

A. Vacca  
*(Bari, I)*

R. Zamarchi  
*(Padua, I)*



08.00 Participant registration

08.30 Presentation of the meeting  
*Chairmen: Franco Dammacco, Franco Silvestris*

## **Introduction**

### **New tools for cancer treatment**

Nuovi strumenti per il trattamento del cancro  
*Franco Silvestris (Bari, I)*

## **WELCOME ADDRESSES**


Michele Emiliano  
President of Apulia Region

Antonio Uricchio  
Rector of the University of Bari

Loreto Gesualdo  
Dean of the Medical Faculty of Bari

Vitangelo Dattoli  
General Director of the University-Hospital 'Policlinico'

09.00 **Cancer incidence in Apulia: treatment potentialities**  
*L'incidenza del cancro in Puglia: sostenibilità e assistenza*  
*Giovanni Gorgoni (Head of Health Welfare Department, Apulia Region)*



# Thursday - June 23<sup>rd</sup>, 2016

## Session 1

### The OMICS revolution: from bench to bedside

La rivoluzione delle scienze "omiche": dal laboratorio al letto del paziente

*Chairmen: Nicoletta Resta (Bari, I), Piersandro Tagliaferri (Catanzaro, I)*

09.30 **Lecture**

#### **The downside of diversity**

Il lato oscuro della forza

*Mariano Rocchi (Bari, I)*

09.55 **Cancer stem cells: role in tumor progression and drug resistance**

Cellule staminali tumorali: ruolo nella progressione tumorale e nella farmacoresistenza

*Ruggero De Maria (Rome, I)*

10.05 **Targeting Hedghog and Notch in colorectal cancer stem cells**

Hedghog e Notch come target molecolari nelle cellule staminali del cancro del colon-retto

*Lucio Miele (New Orleans, USA)*

10.25 **Molecular medicine in the treatment of melanoma**

La medicina molecolare nel trattamento del melanoma

*Paola Queirolo (Genoa, I)*

10.45 Discussion

11.00 Coffee break


11.15 **Lecture**

*Chairmen: Franco Silvestris (Bari, I), Angelo Vacca (Bari, I)*

#### **The evolving spectrum of anti-myeloma treatments: from nitrogen mustards to the targeted therapies**

La terapia del mieloma in evoluzione: dalle mostarde azotate alle terapie "bersaglio"

*Franco Dammacco (Bari, I)*




## **Gastrointestinal cancers: molecular diagnosis and treatment**

Neoplasie gastrointestinali: diagnosi molecolare e trattamento

*Chairmen: Santa Bambace (Barletta, I), Vito Lorusso (Bari, I)*

Session 2

- 11.45 **Lecture**  
**Genomic profiles of pancreatic tumors: role in the management of patients**  
Profili genomici dei tumori pancreatici: ruolo nella gestione dei pazienti  
*Aldo Scarpa (Verona, I)*
- 12.10 **Resistance to EGFR targeting treatments in colorectal cancer**  
La farmaco-resistenza ai trattamenti anti-EGFR nel cancro del colon-retto  
*Alfredo Falcone (Pisa, I)*
- 12.25 **Circulating DNA and protein biomarkers for TKI treatment in metastatic colorectal cancer**  
ctDNA e biomarcatori proteici nella terapia del cancro del colon-retto metastatico con TKI  
*Roberto Labianca (Bergamo, I)*
- 12.45 **Rationale for immunotherapy in gastrointestinal malignancies**  
Razionale dell'immunoterapia nelle neoplasie gastrointestinali  
*Filippo De Braud (Milan, I)*
- 13.05 **Gastric cancers: a molecular roadmap for patient stratification and targeted therapies**  
Il cancro gastrico: profili molecolari per la stratificazione dei pazienti e le terapie bersaglio  
*Giuseppe Aprile (Udine, I)*
- 13.25 **Nanotechnologies and other innovations for the treatment of pancreatic cancer**  
Nanotecnologie e altre innovazioni nelle terapie dei tumori del pancreas  
*Stefano Cascinu (Ancona, I)*
- 13.45 Discussion
- 14.00 Light lunch



Thursday - June 23<sup>rd</sup>, 2016

### Session 3

#### Perspectives in breast cancer genomics

Prospettive nella genomica del cancro mammario

*Chairmen: Mario Brandi (Barletta, I), Saverio Cinieri (Brindisi, I)*

15.00 **Lecture**

#### **Gene profiles of anti-breast cancer immune response**

Profili genetici di risposta immunitaria nel carcinoma mammario

*Francesco Marincola (Doha, Qatar)*

15.25

#### **Overcoming resistance in breast cancer: mTOR inhibitors and new drugs**

Inibitori di mTOR e nuovi farmaci per il superamento della farmaco-resistenza nel carcinoma mammario

*Grazia Arpino (Naples, I)*

15.45

#### **Molecular profiles of triple negative breast cancer: toward personalized therapies**

Profili molecolari del carcinoma mammario 'triple-negative': verso la terapia personalizzata

*Elisabetta Munzone (Milan, I)*

16.05

#### **HER2<sup>+</sup> early breast cancer: from affordable risks and affordable therapies to new developments**

Early breast cancer HER2<sup>+</sup>: dai rischi e dalle terapie accessibili ai nuovi sviluppi

*Pierfranco Conte (Padua, I)*

16.25

#### **Early breast cancer: molecular investigations beyond histology and clinical management**

Approcci terapeutici molecolari nell'Early Breast Cancer

*Filippo Montemurro (Candiolo, I)*

16.45

#### **Role of circulating tumor cells in breast cancer patients**

Ruolo delle cellule tumorali circolanti nel cancro mammario

*Mario Giuliano (Naples, I)*


17.05

Discussion

17.10

Coffee break






## Lung Cancer: role of genomics in clinical practice

Neoplasie polmonari: ruolo della genomica nella pratica clinica

Chairmen: *Evaristo Maiello (San G. Rotondo, I), Giammarco Surico (Lecce, I)*

Session 4

- 17.20 **Lecture**  
**Treatment of early stage lung adenocarcinoma: role of prognostic signatures**  
Terapia dell'adenocarcinoma polmonare in stadio precoce: ruolo dei profili prognostici  
*Giorgio V. Scagliotti (Turin, I)*
- 17.45 **EGFR mutations: best results from second and third generation TKIs**  
Mutazioni di EGFR: i migliori risultati ottenuti con TKIs di seconda e terza generazione  
*Lucio Crinò (Perugia, I)*
- 18.05 **Advanced NSCLC: integrating novel biomarkers into practice**  
NSCLC avanzato: applicazione dei nuovi biomarcatori alla pratica clinica  
*Giuseppe Lo Russo (Milan, I)*
- 18.25 **Gene fusions in NSCLC: ALK, ROS, RET and related treatments**  
Geni di fusione nel NSCLC: ALK, ROS, RET e trattamenti correlati  
*Lorenza Landi (Livorno, I)*
- 18.45 **Anti-PD1 and anti-CTLA4 in NSCLC**  
Anti-PD1 ed anti-CTLA4 nel NSCLC  
*Michele Maio (Siena, I)*
- 19.05 **Circulating tumor cells and ctDNA in NSCLC: a role for treatment decision**  
Cellule tumorali circolanti e ctDNA nel NSCLC: ruolo nella decisione terapeutica  
*Nicola Normanno (Naples, I)*
- 19.25 Discussion



Friday - June 24<sup>th</sup>, 2016

## Session 5

### Genomics in genito-urinary cancer management

Genomica nella gestione delle neoplasie genito-urinarie

*Chairmen: Michele Battaglia (Bari, I), Giuseppe Loverro (Bari, I)*

09.00 **Lecture**

#### **Impact of molecular classification on clinical management of ovarian cancer**

Impatto della classificazione molecolare sulla gestione clinica del carcinoma ovarico

*Jonathan Ledermann (London, UK)*

09.25

#### **Development of PARP inhibitors for BRCA-deficient epithelial ovarian cancer**

Inibitori di PARP nel carcinoma ovarico BRCA-mutato

*Francesco Raspagliesi (Milan, I)*

09.45

#### **TKIs in renal cell carcinoma: what can we expect for the future?**

TKIs nel carcinoma renale: aspettative future

*Camillo Porta (Pavia, I)*

10.05

#### **Emerging immunotherapies for renal cell carcinoma**

Immunoterapie emergenti nel carcinoma renale

*Sergio Bracarda (Arezzo, I)*

10.25

#### **Circulating tumor cells as surrogate biomarker for overall survival in metastatic prostate cancer**

Le cellule tumorali circolanti come sostituto biomarcatore di sopravvivenza nel carcinoma prostatico metastatico

*Johann De Bono (London, UK)*

10.45

#### **Radium-223 dichloride in castration-resistant prostate cancer patients with bone metastases**

Radio-223 nel trattamento del carcinoma prostatico castrazione-resistente con metastasi scheletriche


*Giuseppe Rubini (Bari, I)*

11.05

Discussion

11.10

Coffee break




## Melanoma and sarcoma

Melanoma e sarcoma

*Chairmen: Giuseppe Giudice (Bari, I), Michele Maio (Siena, I)*

Session 6

- 11.20 **Lecture**  
**Personalized treatment in sarcomas**  
Terapia personalizzata dei sarcomi  
*Massimo Aglietta (Turin, I)*
- 11.45 **BRAF-mutant melanoma: treatment approaches and resistance mechanisms**  
Melanoma BRAF mutato: approcci terapeutici e meccanismi di resistenza  
*Michele Del Vecchio (Milan, I)*
- 12.05 **Immunotherapies and novel combinations: advances in the treatment of melanoma**  
Immunoterapie e nuove combinazioni: progressi nel trattamento del melanoma  
*Paolo Ascierto (Naples, I)*
- 12.25 **Immunological and genetic biomarkers: prediction of treatment response**  
Biomarcatori immunologici e genetici come fattori predittivi di risposta al trattamento  
*Marco Tucci (Bari, I)*
- 12.45 **Molecular pathways in melanomagenesis: identification of new therapeutic targets**  
Pathway molecolari coinvolti nella genesi del melanoma: identificazione di nuovi target terapeutici  
*Giuseppe Palmieri (Sassari, I)*
- 13.05 **Personalized medicine in gastrointestinal stromal tumors**  
Terapia personalizzata nei tumori stromali gastrointestinali  
*Maria Abbondanza Pantaleo (Bologna, I)*
- 13.25 Discussion
- 13.45 Light lunch



Friday - June 24<sup>th</sup>, 2016


Session 7

**Oncogenomics in clinical management**

Oncogenomica nella pratica clinica

*Chairmen: Paolo Marchetti (Rome, I), Sabino De Placido (Naples, I)*

- 15.00 **Lecture**  
**Prognostic and predictive role of circulating tumor cells in neuroendocrine tumors**  
Cellule tumorali circolanti nei tumori neuroendocrini: ruolo prognostico e predittivo  
*Tim Meyer (London, UK)*
- 15.25 **Liquid biopsy and genomic assessment: a role in clinical practice?**  
Biopsia liquida e profilo genomico: quale ruolo nella pratica clinica?  
*Paolo Marchetti (Rome, I)*
- 15.45 **Circulating miRNAs as biomarkers in NSCLC**  
miRNA circolanti come biomarcatori nel NSCLC  
*Antonio Russo (Palermo, I)*
- 16.05 **Controversies in clinical applications of circulating tumor cells**  
Controversie nell'applicazione clinica delle cellule tumorali circolanti  
*Rita Zamarchi (Padua, I)*
- 16.25 **Sequencing a single circulating tumor cell for genomic assessment**  
Analisi genomica da una singola cellula tumorale circolante  
*Pamela Pinzani (Florence, I)*
- 16.45 **Adverse events in oncogenomic era: the emesis control**  
Gli eventi avversi nell'era oncogenomica: controllo dell'emesis  
*Monica Montagnani (Bari, I)*




## Toward an oncogenomic network in the Apulia region

Verso la realizzazione di una rete di oncogenomica nella regione Puglia

*Chairmen: Franco Silvestris (Bari, I), Leonardo Resta (Bari, I)*

Workshop

- 17.05 **The Oncogenomic Research Center (CROG) : resources and connections**  
Il Centro Ricerche Oncogenomiche: risorse e collegamenti  
*Franco Silvestris (Bari, I)*
- 17.25 **Results from the first year**  
Risultati del primo anno  
*Raffaele Palmirotta (Bari, I)*
- 17.45 **NSCLC: applications of liquid biopsy**  
Applicazioni della biopsia liquida nel NSCLC  
*Paola Cafforio (Bari, I)*
- 18.05 **CROG: territorial extension and perspectives**  
CROG: estensione territoriale e prospettive  
*Eugenio Maiorano, Nicoletta Resta, Franco Silvestris (CROG, Bari - I)*
- 18.25 Discussion
- 18.45 Concluding remarks



# General Information


## **Scientific Secretariat**

Valeria Simone, Stella D'Oronzo, Sebastiano Acquaviva  
University of Bari, Department of Internal Medicine and Clinical Oncology  
P.za G. Cesare, 11 70124 – Bari  
Ph.: 080-5592909; E-mail: [segreteria.oncologia@uniba.it](mailto:segreteria.oncologia@uniba.it)  
Web: [www.villaromanazzi.it](http://www.villaromanazzi.it)

## **Scientific Board**

Michele Battaglia  
Mario Brandi  
Ettore Cicinelli  
Franco Dammacco  
Giuseppe Giudice  
Vito Lorusso  
Giuseppe Loverro  
Eugenio Maiorano  
Nicola Palasciano  
Leonardo Resta  
Nicoletta Resta  
Franco Silvestris  
Angelo Vacca

# General Information



## **VENUE**

Villa Romanazzi Carducci  
Via G. Capruzzi 326, Bari (Italy)  
Ph.: +39.080.5427400

## **REGISTRATION**

Registration is free but mandatory. It includes: participation in scientific sessions, congress kit, coffee break, light lunch and certificate of attendance.

Applications for registration will be processed in the order they are received.

Please send applications to the Organizing Secretariat by fax.

Incomplete applications or applications submitted in any other form will not be accepted.

Attendants shall check that places are available and that their registration has been finalized.


## **CME**

A number of 12.8 credits have been assigned to this Congress.

This scientific event is for 150 Physicians specialized in Internal Medicine, Oncology, Urology, Gastroenterology, Geriatrics, General Surgery, Thoracic Surgery, Medical Genetics, Pathologic Anatomy, Clinical Pathology and Biology.

Please note that CME credits will be acquired and certified once the following requirements have been fulfilled:

- participation in the entire training event (100% of total hours);
- complete documentation entirely filled in;
- passing the CME evaluation questionnaire (minimum passing score 80%).



# Notes

---

---

---

---

---

---

---

---

---

---

---

---

---

---



**Scheda di adesione**

da inviare compilata in stampatello a:

**e20econvegni s.r.l.**

Via Tasselgardo, 68 - 76125 Trani (BT)

fax 0883.954388 - mail: info@e20econvegni.it

COGNOME \_\_\_\_\_ NOME \_\_\_\_\_

 **MEDICO CHIRURGO specialista in:**

- MEDICINA INTERNA   
  ONCOLOGIA   
  UROLOGIA   
  GERIATRIA   
  GASTROENTEROLOGIA   
  CHIRURGIA GENERALE  
 ANATOMIA PATOLOGICA   
  GENETICA MEDICA   
  PATOLOGIA CLINICA   
  CHIRURGIA TORACICA

 **BIOLOGO**

REPARTO ED ENTE DI APPARTENENZA \_\_\_\_\_

TEL. \_\_\_\_\_ FAX. \_\_\_\_\_ CITTÀ \_\_\_\_\_ C.A.P. \_\_\_\_\_

**Dati necessari per ECM**

CODICE FISCALE \_\_\_\_\_ INDIRIZZO AB. \_\_\_\_\_

CITTÀ \_\_\_\_\_ C.A.P. \_\_\_\_\_ CELL. \_\_\_\_\_

EMAIL \_\_\_\_\_

- dichiaro, in qualità di dipendente di struttura sanitaria, di aver ottemperato agli obblighi in materia di informativa all'Ente di appartenenza   
  dichiaro di non essere dipendente di struttura sanitaria e di non essere assoggettato all'obbligo di segnalazione all'Ente di appartenenza

Invitato dall'Azienda (sponsor) \_\_\_\_\_

N.B. Il monte crediti formativi ECM nel triennio 2014-2016, pari a n.150, è acquisibile solo per 1/3 su invito diretto delle Aziende


Autorizzo il trattamento dei miei dati personali ai sensi del D. lgs 169/2003

DATA \_\_\_\_\_

FIRMA \_\_\_\_\_







Organizing Secretariat and Provider (n. 432)

**E20**  
convegni  
e20econvegni s.r.l.

Via Tasselgardo, 68 - 76125 Trani (BT)

Tel: 0883.954886 - 392.9984388 Fax: 0883.954388

Web: [www.e20econvegni.it](http://www.e20econvegni.it) - Mail: [info@e20econvegni.it](mailto:info@e20econvegni.it)